TD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Dan Brennan maintains a Hold rating on Myriad Genetics (NASDAQ:MYGN) and raises the price target from $28 to $30.
August 07, 2024 | 9:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TD Cowen analyst Dan Brennan maintains a Hold rating on Myriad Genetics and raises the price target from $28 to $30.
The raised price target from $28 to $30 indicates a positive outlook from the analyst, which could lead to a short-term increase in stock price. However, the Hold rating suggests limited upside potential.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100